Cogentix Medical (CGNT) Earning Somewhat Critical News Coverage, Report Finds
News stories about Cogentix Medical (NASDAQ:CGNT) have been trending somewhat negative recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cogentix Medical earned a media sentiment score of -0.23 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 46.536749186373 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Cogentix Medical (CGNT) traded down $0.04 during midday trading on Friday, hitting $2.94. The stock had a trading volume of 48,812 shares, compared to its average volume of 76,490. The company has a market cap of $179.06, a PE ratio of -7.17 and a beta of 0.91. Cogentix Medical has a 12 month low of $1.55 and a 12 month high of $3.34.
Several brokerages have weighed in on CGNT. TheStreet upgraded Cogentix Medical from a “d+” rating to a “c” rating in a research note on Thursday, November 9th. Zacks Investment Research cut Cogentix Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, December 20th. Roth Capital started coverage on Cogentix Medical in a research note on Wednesday, November 8th. They set a “buy” rating and a $4.00 target price on the stock. JMP Securities started coverage on Cogentix Medical in a research note on Friday, October 6th. They set an “outperform” rating and a $5.00 target price on the stock. Finally, Aegis started coverage on Cogentix Medical in a research note on Friday, December 1st. They set a “buy” rating and a $4.75 target price on the stock. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. Cogentix Medical has a consensus rating of “Buy” and a consensus price target of $4.06.
COPYRIGHT VIOLATION WARNING: “Cogentix Medical (CGNT) Earning Somewhat Critical News Coverage, Report Finds” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/01/13/cogentix-medical-cgnt-earning-somewhat-critical-news-coverage-report-finds.html.
About Cogentix Medical
Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).
Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.